
Sign up to save your podcasts
Or


Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyond.
Read the full article at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00233-6/fulltext?dgcid=buzzsprout_icw_podcast_10-06-25_laninf
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet GroupLeonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyond.
Read the full article at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00233-6/fulltext?dgcid=buzzsprout_icw_podcast_10-06-25_laninf
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

7,625 Listeners

879 Listeners

140 Listeners

325 Listeners

497 Listeners

130 Listeners

3,369 Listeners

112,611 Listeners

56,603 Listeners

93 Listeners

368 Listeners

21 Listeners

0 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

2 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

32 Listeners

83 Listeners

3 Listeners

0 Listeners

5 Listeners

0 Listeners

0 Listeners

0 Listeners